Belmont, CA, United States of America

Anthony C Allison

This inventor holds 31 USPTO granted patents, primarily in Modified Annexin Proteins. Top assignees: Syntex (u.s.a.) Inc., Alavita Pharmaceuticals, Inc., Alavita Pharmaccuticals, Inc.. Active years: 1986-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anthony C Allison. Retrieved from https://idiyas.com/inventor/anthony-c-allison

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 74.2

Average Co-Inventor Count = 2.2

ph-index = 17

Forward Citations = 600(Granted Patents)


Company Filing History:


Years Active: 1986-2010

Loading Chart...
Areas of Expertise:
Modified Annexin Compositions
Organ Transplantation
Reperfusion Injury
Vaso-Occlusive Disease
Thrombosis Prevention
Autoimmune Inflammatory Diseases
Mycophenolic Acid
Monoclonal Antibodies
Vaccine Adjuvants
Feline Leukemia Virus
Malignant Cell Detection
Pharmaceutical Derivatives
31 patents (USPTO):Explore Patents

Title: **The Innovative Contributions of Anthony C. Allison**

Introduction

Anthony C. Allison, located in Belmont, CA, is a prolific inventor known for his significant contributions to the field of biomedical research, particularly in the development of modified annexin proteins. With a remarkable portfolio of 31 patents, his innovations focus on improving medical outcomes in critical areas such as thrombosis prevention and ischemia-reperfusion injury.

Latest Patents

His latest patents include sophisticated modified annexin compositions and methods for their utilization. These modified annexin proteins, notably a homodimer of human annexin V, are designed to prevent thrombosis without raising the risk of hemorrhage. They enhance the storage and transfusion survivability of platelets and mitigate ischemia-reperfusion injury (IPI). By binding to phosphatidylserine (PS) on cell surfaces, these modified annexins prevent the assembly of the prothrombinase complex, effectively reducing leukocyte and platelet binding during post-ischemic reperfusion. Consequently, this innovation aids in restoring microvascular blood flow and minimizing organ damage.

Additionally, these modified annexin proteins have significant implications for organ transplantation, where they help prevent thrombosis and address complications associated with IPI, thereby enhancing patient outcomes and organ viability.

Career Highlights

Anthony C. Allison has had a distinguished career with notable stints at reputable firms such as Syntex (U.S.A.) Inc. and Alavita Pharmaceuticals, Inc. His work in these organizations has paved the way for ground-breaking advancements in the medical and pharmaceutical fields, reflecting his commitment to innovation and improvement in healthcare solutions.

Collaborations

Throughout his career, Allison has collaborated with notable professionals in the field, including Elsie M. Eugui and Peter H. Nelson. These partnerships have fostered a collaborative environment that enhances research and aids in the development of revolutionary inventions, exemplifying the importance of teamwork in scientific progress.

Conclusion

Anthony C. Allison's extensive patent portfolio and collaborative efforts underscore his vital role in advancing medical science through innovative inventions. His work continues to have a profound impact on technology related to thrombosis prevention and organ transplantation, highlighting the transformative power of his contributions in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…